Pillstats
Rx only · Tablet, Film Coated, Extended Release · Oral

Doxazosin Mesylate

Brands: Cardura Xl · Doxazosin Mesylate

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)49276
US makers1 labelers
Packages2
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$2.01$4.02$6.03$8.05Jan 2026Jun 2026Jul 2026
$6.997
Latest avg · Jul 22, 2026
+0%
Since Jan 1, 2026
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

n/an/a2855831102025 Q12025 Q22025 Q32025 Q42026 Q1
96
Rx · 2026 Q1
4.5K
Units dispensed
3
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Viatris Specialty LLCunknown2SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Dec 23, 2024
    RECALLRecall (Class II): Cardura XL (doxazosin) extended release tablets 8 mg, 30-count bottle, Rx only, Distributed by Viatris Specialty LLC, M…

    Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing. — Recalling firm: Viatris Inc — USA nationwide.

  • Dec 23, 2024
    RECALLRecall (Class II): Cardura XL (doxazosin) extended release tablets 4 mg, 30 -count bottle, Rx only, Distributed by Viatris Specialty LLC, …

    Failed Impurities/Degradation Specifications: Out of specification results observed for the impurity compound B during stability testing. — Recalling firm: Viatris Inc — USA nationwide.